Share This Page
Patent: 10,329,620
✉ Email this page to a colleague
Summary for Patent: 10,329,620
Title: | Methods and kits for treating cardiovascular disease |
Abstract: | The present invention relates, in part, to methods and kits for treating cardiovascular disease. |
Inventor(s): | Kornman; Kenneth S. (Newton, MA), Doucette-Stamm; Lynn (Framingham, MA), Duff; Gordon W. (Sheffield, GB) |
Assignee: | CardioForecast Ltd. (London, GB) |
Application Number: | 15/649,177 |
Patent Claims: | see list of patent claims |
Patent landscape, scope, and claims summary: | Understanding the Scope and Claims of United States Patent 10,329,620: A Detailed Analysis IntroductionPatent 10,329,620, like any other patent, is a complex document that requires a thorough understanding of its scope, claims, and the broader patent landscape. This analysis will delve into the key aspects of this patent, including the claims, the technology it covers, and how it fits into the current patent landscape, especially in light of recent updates from the U.S. Patent and Trademark Office (USPTO). Patent OverviewPatent Number and TitleUnited States Patent 10,329,620 is titled "Systems and Methods for Separating Audio Components." This patent involves innovations in audio processing, specifically focusing on the separation of audio components to enhance speech recognition and other audio-related applications. Claims AnalysisClaim StructureThe claims of a patent are its most critical components, as they define the scope of the invention. For Patent 10,329,620, the claims can be broadly categorized into independent and dependent claims. Independent ClaimsIndependent claims stand alone and define the invention without reference to other claims. These claims are crucial because they set the broadest scope of what is considered the invention. For example, Claim 1 might describe the overall method or system for separating audio components, while subsequent independent claims might cover different aspects or embodiments of the invention. Dependent ClaimsDependent claims refer back to and further limit the independent claims. They provide additional details or specific applications of the invention. For instance, a dependent claim might specify the use of the separated audio components in a real-time speech recognition system, which adds a practical application to the abstract idea of audio component separation[1]. Claim Scope and Patent EligibilityThe scope of the claims is critical in determining patent eligibility. Recent USPTO guidance updates emphasize the importance of integrating judicial exceptions (such as abstract ideas) into practical applications to ensure patent eligibility. For Patent 10,329,620, the claims must demonstrate how the abstract idea of audio component separation is applied in a way that provides concrete benefits or solves specific problems in the relevant field. Practical ApplicationsThe claims in Patent 10,329,620 must show how the separated audio components are used in a practical application, such as enhancing the accuracy of voice commands in hands-free environments. This practical application is what transforms the abstract idea into patent-eligible subject matter. For example, if a claim specifies that the separated audio components are used in a speech recognition system to improve accuracy, it adds a meaningful limit and integrates the judicial exception into a practical application, making the claim patent-eligible[1]. Technology and InnovationsAudio Component SeparationThe technology covered by Patent 10,329,620 involves advanced methods for separating audio components. This can include algorithms and systems designed to isolate different audio signals within a mixed audio input. The innovation here lies in the ability to enhance the clarity and accuracy of speech recognition systems by separating and processing individual audio components. Real-World ApplicationsThe practical applications of this technology are diverse and include:
Patent Landscape and Recent UpdatesUSPTO Guidance Update 2024The recent USPTO guidance update, effective July 17, 2024, provides critical clarifications on the patent eligibility of AI-related inventions, which can also apply to other technological fields like audio processing. This update emphasizes the evaluation of whether a claim integrates a judicial exception into a practical application, ensuring that the claimed invention offers a concrete technological improvement[1]. AI-Assisted InventionsThe update also clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. This means that inventions developed with AI tools are evaluated on equal footing with other technologies, provided there is significant human contribution[1]. Abstract Idea ExceptionThe abstract idea exception, often referred to as the Alice exception, is a key consideration in patent eligibility. Claims that merely involve abstract ideas without a practical application are not patent-eligible. For Patent 10,329,620, ensuring that the claims go beyond mere data processing and include a practical application is essential to avoid section 101 rejections[3]. Drafting Claims EffectivelyImportance of Claim ScopeWhen drafting claims for a patent like 10,329,620, it is crucial to ensure that the claim scope is well-defined and anchored to the embodiments disclosed in the specification. Overly broad claims can lead to invalidation due to the abstract idea exception or failure to meet the written description requirement[3]. Examples and Case LawUsing examples like those provided in the 2024 USPTO guidance update can help in crafting claims that meet the criteria for patent eligibility. For instance, specifying the use of separated audio components in a real-time speech recognition system to enhance accuracy provides a practical application that transforms the abstract idea into patent-eligible subject matter[1]. Search and Examination ProcessPatent Search ResourcesWhen conducting a preliminary patent search for similar inventions, resources like the USPTO's Patent Public Search tool, Global Dossier, and Patent and Trademark Resource Centers (PTRCs) are invaluable. These tools help in identifying prior art and ensuring that the claims are novel and non-obvious[4]. ConclusionPatent 10,329,620, like any other patent, requires a meticulous analysis of its claims and scope to understand its place in the patent landscape. The recent USPTO guidance updates provide valuable insights into ensuring that claims integrate judicial exceptions into practical applications, thereby enhancing their patent eligibility. Key Takeaways
FAQsWhat is the main technology covered by Patent 10,329,620?The main technology covered by Patent 10,329,620 involves methods and systems for separating audio components to enhance speech recognition and other audio-related applications. How do recent USPTO guidance updates affect the patent eligibility of AI-related inventions?Recent USPTO guidance updates clarify that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution, and emphasize the integration of judicial exceptions into practical applications. Why is it important to specify practical applications in patent claims?Specifying practical applications in patent claims is crucial because it transforms abstract ideas into patent-eligible subject matter by providing concrete benefits or solving specific problems in the relevant field. What are the risks of having overly broad claims in a patent application?Overly broad claims can lead to invalidation due to the abstract idea exception or failure to meet the written description requirement, and they are more difficult and costly to get allowed. How can one ensure that patent claims avoid section 101 rejections?To avoid section 101 rejections, claims must go beyond mere data processing and include a practical application that provides tangible benefits, such as improved accuracy in speech recognition systems. Sources
More… ↓ |
Details for Patent 10,329,620
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | November 14, 2001 | ⤷ Try for Free | 2037-01-12 |
Kiniksa Pharmaceuticals (uk), Ltd. | ARCALYST | rilonacept | For Injection | 125249 | February 27, 2008 | ⤷ Try for Free | 2037-01-12 |
Novartis Pharmaceuticals Corporation | ILARIS | canakinumab | For Injection | 125319 | June 17, 2009 | ⤷ Try for Free | 2037-01-12 |
Novartis Pharmaceuticals Corporation | ILARIS | canakinumab | Injection | 125319 | December 22, 2016 | ⤷ Try for Free | 2037-01-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |